HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BIOA

BioAge Labs Inc

Last Close
Mar 06  •  04:00PM ET
20.29
Dollar change
-0.09
Percentage change
-0.44 %
Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD
Held by: VTI IWM VXF IBB IWN FESM SCHA DWAS VTWO VFMO
Scroll to Statements
IndexRUT P/E- EPS (ttm)-2.11 Insider Own30.51% Shs Outstand35.85M Perf Week-8.89%
Market Cap847.16M Forward P/E- EPS next Y-2.78 Insider Trans-2.82% Shs Float29.01M Perf Month0.69%
Enterprise Value568.51M PEG- EPS next Q-0.74 Inst Own35.72% Short Float4.62% Perf Quarter120.07%
Income-75.79M P/S143.10 EPS this Y65.81% Inst Trans6.35% Short Ratio1.95 Perf Half Y330.79%
Sales5.92M P/B2.62 EPS next Y-22.48% ROA-23.59% Short Interest1.34M Perf YTD53.36%
Book/sh7.74 P/C2.96 EPS next 5Y25.50% ROE-25.64% 52W High24.00 -15.46% Perf Year351.89%
Cash/sh6.84 P/FCF- EPS past 3/5Y-30.62% - ROIC-27.08% 52W Low2.88 604.51% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin96.77% Volatility7.56% 7.19% Perf 5Y-
Dividend TTM- EV/Sales96.03 EPS Y/Y TTM-1.89% Oper. Margin-1516.29% ATR (14)1.45 Perf 10Y-
Dividend Ex-Date- Quick Ratio11.87 Sales Y/Y TTM- Profit Margin-1280.90% RSI (14)50.79 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio11.87 EPS Q/Q17.81% SMA20-2.06% Beta1.37 Target Price46.60
Payout- Debt/Eq0.03 Sales Q/Q- SMA508.18% Rel Volume0.70 Prev Close20.38
Employees64 LT Debt/Eq0.01 EarningsNov 06 AMC SMA200120.36% Avg Volume689.58K Price20.29
IPOSep 26, 2024 Option/ShortYes / Yes EPS/Sales Surpr.4.04% 164.18% Trades Volume484,086 Change-0.44%
Date Action Analyst Rating Change Price Target Change
Feb-25-26Initiated Oppenheimer Outperform $60
Feb-18-26Upgrade Jefferies Hold → Buy $62
Jan-27-26Initiated Piper Sandler Overweight $73
Dec-05-25Upgrade Morgan Stanley Underweight → Equal-Weight $12
Oct-22-25Upgrade Citigroup Neutral → Buy $10
Feb-28-25Initiated William Blair Mkt Perform
Dec-10-24Downgrade Morgan Stanley Overweight → Underweight $40 → $5
Dec-09-24Downgrade Jefferies Buy → Hold $42 → $7
Dec-09-24Downgrade Citigroup Buy → Neutral $45 → $7
Oct-21-24Initiated Morgan Stanley Overweight $40
Show Previous Ratings
Feb-26-26 10:07PM
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion
(MarketBeat)
Feb-19-26 04:30PM
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
(GlobeNewswire)
Jan-29-26 03:00AM
Eli Lilly, BioAge chase NLRP3 inhibitors with pipeline in a pill potential
(Pharma Voice)
Jan-21-26 10:30PM
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
(GlobeNewswire) -5.63% -6.06%
Jan-20-26 04:01PM
BioAge Announces Proposed Public Offering
(GlobeNewswire) +5.75%
09:00AM Loading…
09:00AM
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
(GlobeNewswire)
Jan-12-26 01:06PM
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
(Investor's Business Daily) +27.23%
09:00AM
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
(GlobeNewswire)
Dec-13-25 10:35AM
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole
(Motley Fool)
Dec-04-25 09:00AM
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
(GlobeNewswire) +13.88%
Nov-25-25 04:30PM
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
(GlobeNewswire)
Nov-07-25 09:00AM
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
(GlobeNewswire)
Nov-06-25 04:45PM
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
(GlobeNewswire)
Nov-05-25 07:45AM
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy
(Motley Fool)
Oct-29-25 06:15AM
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?
(Motley Fool)
06:33PM Loading…
Oct-26-25 06:33PM
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?
(Motley Fool)
Oct-23-25 07:36AM
Ventyx shares soar after study suggests cardiovascular benefits for experimental drug
(BioPharma Dive) +31.40%
Aug-20-25 04:30PM
BioAge Labs to Present at Upcoming Investor Conferences
(GlobeNewswire)
Aug-18-25 07:36AM
BioAge commences dosing in trial of obesity treatment candidate BGE-102
(Clinical Trials Arena)
Aug-15-25 09:00AM
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
(GlobeNewswire)
Aug-06-25 04:30PM
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
(GlobeNewswire)
Jul-29-25 10:23AM
BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery
(Insider Monkey)
Jun-21-25 06:00PM
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
(GlobeNewswire)
Jun-17-25 09:00AM
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
(GlobeNewswire)
Jun-03-25 09:00AM
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
(GlobeNewswire)
May-30-25 09:05AM
BioAge Labs completes IND-enabling studies for BGE-102
(TipRanks)
May-29-25 11:18PM
BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025
(Insider Monkey)
09:00AM
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
(GlobeNewswire)
May-27-25 04:30PM
BioAge Labs to Present at Upcoming Investor Conferences
(GlobeNewswire)
May-06-25 04:30PM
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
(GlobeNewswire)
01:02PM Loading…
Apr-21-25 01:02PM
BioAge Labs, Inc. (BIOA): A Bull Case Theory
(Insider Monkey)
Mar-22-25 11:00AM
Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings
(SeekingAlpha)
Mar-20-25 04:30PM
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
(GlobeNewswire)
Mar-17-25 01:54PM
BioArctic receives Orphan Drug Designation for exidavnemab the US
(PR Newswire)
Mar-04-25 05:07AM
BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman
(Newsfile)
Feb-20-25 04:30PM
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
(GlobeNewswire)
10:36AM
BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman
(Newsfile)
Feb-16-25 07:18AM
BIOA COURT NEWS: BioAge Labs has been Sued for Securities Violations; Contact BFA Law by March 10 if You Lost Money (NASDAQ:BIOA)
(GlobeNewswire)
Feb-14-25 05:45AM
Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA
(PR Newswire) +5.97%
Feb-13-25 08:42AM
BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman
(Newsfile)
Feb-07-25 05:45AM
BioAge Labs, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA
(PR Newswire)
Jan-30-25 09:01AM
BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman
(Newsfile)
Jan-29-25 05:39AM
BioAge drops obesity drug; Akero, 89bio cash in on MASH data
(BioPharma Dive) -6.40%
Jan-28-25 07:27PM
Kessler Topaz Meltzer & Check, LLP Encourages BioAge Labs, Inc. Investors with Losses to Contact the Firm
(PR Newswire)
09:00AM
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
(GlobeNewswire)
Jan-24-25 05:45AM
Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA
(PR Newswire)
Jan-22-25 03:00AM
After an obesity stumble, BioAge reconnects with its longevity pipeline
(Pharma Voice)
Jan-21-25 05:45AM
Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA
(PR Newswire)
Jan-18-25 03:07AM
BIOAGE LABS (BIOA) Investors are Notified the Company has been Sued and are Urged to Contact BFA Law by March 10
(Newsfile)
Jan-06-25 09:00PM
Bragar Eagel and Squire, P.C. Is Investigating Franklin, MediaAlpha, e.l.f. Beauty, and BioAge and Encourages Investors to Contact the Firm
(GlobeNewswire) -7.39%
Jan-03-25 12:51PM
BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman
(PR Newswire)
Jan-02-25 09:35AM
BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-01-25 05:00AM
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman
(Newsfile)
Dec-27-24 11:32AM
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman
(GlobeNewswire) -6.46%
09:18AM
BioAge Labs, Inc. (BIOA): A Bull Case Theory
(Insider Monkey)
Dec-26-24 07:23AM
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against BioAge Labs, Inc. (BIOA)
(Newsfile)
Dec-25-24 07:04AM
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman
(Newsfile)
Dec-23-24 10:19AM
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman
(GlobeNewswire)
Dec-19-24 01:15PM
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman
(GlobeNewswire) +20.23%
05:46AM
BioAge and Novartis seek drug targets for ageing-related diseases
(Pharmaceutical Technology)
Dec-18-24 09:00AM
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
(GlobeNewswire)
Dec-16-24 04:20PM
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman
(GlobeNewswire)
03:00AM
3 closely watched drugs that failed in the clinic
(Pharma Voice)
Dec-13-24 10:31AM
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman
(Newsfile) -6.75%
Dec-12-24 06:34PM
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman
(GlobeNewswire)
Dec-09-24 07:51PM
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman
(GlobeNewswire) -76.85%
09:28AM
BioAge halts ongoing Phase II trial of obesity drug due to liver concerns
(Clinical Trials Arena)
07:41AM
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
(Benzinga)
Dec-07-24 06:34AM
BioAge shares tumble after decision to halt obesity drug study
(BioPharma Dive)
Dec-06-24 04:35PM
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
(GlobeNewswire) +9.36% -76.85%
Dec-05-24 04:30PM
BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic
(GlobeNewswire)
Dec-04-24 04:47PM
Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now?
(Insider Monkey)
Nov-21-24 04:30PM
BioAge Labs to Present at Upcoming Investor Conferences
(GlobeNewswire)
Nov-12-24 11:01PM
BioAge Labs Reports Strong Q3 2024 Achievements
(TipRanks) -11.78%
Nov-07-24 04:30PM
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire) -10.11% +7.61%
Nov-04-24 09:00AM
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
(GlobeNewswire)
Oct-24-24 09:00AM
BioAge Labs to Present at Jefferies London Healthcare Conference
(GlobeNewswire)
Oct-21-24 10:53AM
Wall Street analysts initiate coverage of BioAge Labs
(Investing.com) +8.26%
Oct-17-24 09:45AM
Prediction: These 2 Stocks Could Soar in 2025
(Motley Fool)
Oct-12-24 02:31PM
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
(Motley Fool)
Oct-07-24 09:10PM
RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc
(GuruFocus.com)
Oct-05-24 07:15AM
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October
(Motley Fool)
Oct-03-24 09:05AM
This IPO Biotech Stock Could Be the Next Eli Lilly
(Motley Fool) +5.73%
Oct-01-24 04:30PM
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
(GlobeNewswire)
Sep-26-24 04:08PM
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO
(Investor's Business Daily)
02:36PM
A weight loss drug developer's stock soars after a $198 million IPO
(Quartz)
08:25AM
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
(FastCompany)
Sep-25-24 08:00PM
BioAge Labs Announces Pricing of Upsized Initial Public Offering
(GlobeNewswire)
04:13PM
BioAge prices $198M IPO, validating pivot to obesity drug research
(BioPharma Dive)
11:27AM
A weight loss drug maker is aiming for a big IPO
(Quartz)
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RUBIN PAUL DChief Medical OfficerMar 02 '26Option Exercise4.777,43335,4707,433Mar 03 04:46 PM
RUBIN PAUL DChief Medical OfficerMar 02 '26Sale20.307,433150,8900Mar 03 04:46 PM
GOLDSTEIN DOV A MDChief Financial OfficerMar 01 '26Option Exercise4.383,54215,51433,033Mar 03 04:44 PM
RUBIN PAUL DOfficerMar 02 '26Proposed Sale20.037,433148,883Mar 02 10:17 AM
RUBIN PAUL DChief Medical OfficerFeb 02 '26Option Exercise4.777,43335,4707,433Feb 03 04:26 PM
RUBIN PAUL DChief Medical OfficerFeb 02 '26Sale18.757,433139,3690Feb 03 04:26 PM
GOLDSTEIN DOV A MDChief Financial OfficerFeb 01 '26Option Exercise4.383,54115,51029,491Feb 03 04:23 PM
RUBIN PAUL DOfficerFeb 02 '26Proposed Sale18.757,433139,369Feb 02 09:43 AM
GOLDSTEIN DOV A MDChief Financial OfficerJan 16 '26Option Exercise4.383,54215,51425,950Jan 21 04:20 PM
GOLDSTEIN DOV A MDChief Financial OfficerJan 13 '26Option Exercise8.3927,000226,53049,408Jan 15 04:22 PM
GOLDSTEIN DOV A MDChief Financial OfficerJan 13 '26Sale19.7027,000531,82822,408Jan 15 04:22 PM
Fortney KristenChief Executive OfficerJan 13 '26Sale18.12233,1074,223,036976,949Jan 15 04:20 PM
Fortney Kristen10% OwnerJan 13 '26Proposed Sale18.00233,1074,195,926Jan 13 04:36 PM
GOLDSTEIN DOV A MDOfficerJan 13 '26Proposed Sale19.7027,000531,828Jan 13 04:16 PM
RUBIN PAUL DChief Medical OfficerJan 02 '26Option Exercise4.777,43335,4707,433Jan 06 04:24 PM
RUBIN PAUL DChief Medical OfficerJan 02 '26Sale12.857,43395,4900Jan 06 04:24 PM
RUBIN PAUL DOfficerJan 02 '26Proposed Sale13.417,43399,677Jan 02 12:56 PM
RUBIN PAUL DChief Medical OfficerDec 09 '25Option Exercise6.5718,000118,26018,000Dec 11 04:21 PM
RUBIN PAUL DChief Medical OfficerDec 09 '25Sale12.0018,000216,0000Dec 11 04:21 PM
RUBIN PAUL DOfficerDec 09 '25Proposed Sale12.0018,000216,000Dec 09 11:23 AM
RUBIN PAUL DChief Medical OfficerDec 04 '25Option Exercise4.1168,897283,16768,897Dec 05 06:20 PM
RUBIN PAUL DChief Medical OfficerDec 04 '25Sale10.1968,897701,9090Dec 05 06:20 PM
RUBIN PAUL DOfficerDec 04 '25Proposed Sale10.1968,897701,912Dec 04 04:30 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)